Delcath Systems rises on positive data on cancer drug

Delcath Systems

02/12/2021 13:49

** Shares of drug developer  DCTH.O  up ~1.5% at $9.86
premarket 
    ** Co announces positive results from late-stage study of
drug candidate, Hepzato, for treating an extremely rare form of
cancer that affects the eye  urn:newsml:reuters.com:*:nGNX226NC4 
    ** Treatment with Hepzato showed an objective response rate
of 35.2% vs 12.5% for the group treated with alternative care,
meaning that tumors shrank more for patients who took the drug
    ** Hepzato treated patients showed median progression free
survival, or the time a patient lived without their cancer
becoming worse, of 9.03 months vs 3.12 months for alternative
care group
    ** Co expects to resubmit marketing application for Hepzato
by mid-2022
    ** Up to Wednesday's close, stock had fallen 45.81% YTD 

    

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))